Edity Therapeutics
PrivateLast Round
Series A
Extension
Dec 29, 2023
Est. Valuation
$30.96M
Total Funding Raised
$13.63M
Company Overview
Edity Therapeutics operates in Healthcare & Life Sciences and is based in Israel. Its latest recorded funding round was a Series A Extension round in December 2023.
Edity Therapeutics is a biotechnology company that harnesses the immune system to deliver therapeutic proteins directly to the cytoplasm of target cells to reprogram cells and tissue back to health.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Edity Therapeutics Comparables
Compare Edity Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NanoSyrinx | 86% | |
| Gensaic | 80% | |
| ILIAS Biologics Inc. | 79% |
For institutional investors. Book with your work email.
Edity Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Dec 29, 2023 | ||||
| Crowdfunding | Oct 24, 2023 | ||||
| Grant | Jul 28, 2023 | ||||
| Seed | Sep 1, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Edity Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NFX | Seed |
| Israel Innovation Authority | Grant |
| Gaingels | Crowdfunding, Seed |
| Tal Ventures | Seed |
| Reinforced Ventures | Crowdfunding |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 20, 2026
Monthly visitors increased 341% MoM.
- Nov 8, 2025
Monthly visitors increased 466% MoM.
For institutional investors. Book with your work email.
Edity Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Edity Therapeutics's valuation, stock price, and market status.
Is Edity Therapeutics a public or private company?
Edity Therapeutics is a private company.
What is the current stock price of Edity Therapeutics?
Edity Therapeutics is a private company, so its shares have no public market price. Caplight tracks Edity Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Edity Therapeutics worth (valuation)?
Edity Therapeutics's valuation is estimated at $31.0M based on funding round data.
Can I buy Edity Therapeutics stock?
Edity Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Edity Therapeutics's last funding round?
Edity Therapeutics's most recent funding round was Series A Extension on December 29, 2023.
Who are the main investors in Edity Therapeutics?
Key investors in Edity Therapeutics include NFX, Israel Innovation Authority, Gaingels, Tal Ventures, Reinforced Ventures.
Will Edity Therapeutics IPO soon?
No public IPO plans have been announced for Edity Therapeutics.
How can I track Edity Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Edity Therapeutics's shares on secondary markets.